CoE Publication in Nature Microbiology: Parkinson’s Drug Disrupts Gut Microbiome

CoE Publication in Nature Microbiology: Parkinson’s Drug Disrupts Gut Microbiome

A new study, conducted within the framework of the CoE Microplanet and published in Nature Microbiology, reveals how the Parkinson’s drug entacapone disrupts the gut microbiome by inducing iron deficiency, favoring pathogenic microbes like E. coli.

Chemical imaging of active gut microbes. After brief incubation with heavy water, culture medium and a drug, various chemical bonds (here C-D and C-H) in the stool sample are shown in yellow and green, their ratio in yellow-purple (left). Selected microbes are detected in the same image section with fluorescence-labelled oligonucleotide probes in cyan. The activity of the detected microbes can be determined based on the amount of C-D bonds. ©Xiaowei Ge (Boston University)

The research, led by Michael Wagner from the Centre for Microbiology and Environmental Systems Science (CeMESS) at the University of Vienna in collaboration with CeMESS members and international partners from the UK, Denmark, and the US highlights the often-overlooked effects of human-targeted drugs on microbial communities. Using a novel experimental approach, the team discovered that entacapone triggers iron starvation in the gut, promoting the growth of bacteria adapted to low-iron conditions. This groundbreaking study offers insights into how certain drugs can unintentionally alter the gut microbiome and suggests strategies to mitigate these effects.

Newsletter

Follow the latest developments in the CoE Microplanet.

Find out about CoE seminars, presentations and events open to the public.

Subscription Form